Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity

Carlo L. Maini, Rosa Sciuto, Alessandro Ferraironi, Patrizia Vici, Anna Tofani, Anna Festa, Francesca Conti, Massimo Lopez

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background. Cardiotoxicity is the major limiting factor in anthracycline chemotherapy of advanced neoplastic disease. Epirubicin shows a more favorable therapeutic index than does doxorubicin, but it is still cardiotoxic. Limited data regarding epirubicin cardiotoxicity are available, and suggested guidelines for doxorubicin with left ventricular ejection fraction (LVEF) measurement may not be empirically useful for epirubicin therapy. This study evaluates the diagnostic role of antimyosin immunoscintigraphy for early identification of patients at risk for late pump dysfunction from cardiotoxicity induced by high-dose administration of epirubicin up to high cumulative dosages. Methods and Results. Chemotherapy with epirubicin was administered to 36 patients with cancer at a dosing rate of 160 mg/m2 as a bolus injection every 21 days to a cumulative dosage of 960 mg/m2. Radionuclide angiography (LVEF) and antimyosin immunoscintigraphy with heart-lung ratio (HLR) measurements were performed before chemotherapy, at intermediate cumulative epirubicin dosages, at the end of treatment, and during the follow-up, LVEF decreased significantly at the end of the treatment and after therapy discontinuation. HLR values were significantly increased at intermediate epirubicin dosage levels and continued to increase to the end of the treatment but thereafter remained substantially unmodified for 3 to 6 months after therapy discontinuation. A value of HLR > 1.85 at intermediate epirubicin dosage level showed a sensitivity of 95% and a specificity of 57% as a predictor of late LVEF impairment. Conclusions. LVEF appears more useful at high cumulative dosages and during follow-up to monitor late pump dysfunction, whereas HLR may be effective during the early phase of the therapy in determining which patients are at risk for development of late cardiac dysfunction.

Original languageEnglish
Pages (from-to)502-508
Number of pages7
JournalJournal of Nuclear Cardiology
Volume4
Issue number6
DOIs
Publication statusPublished - Nov 1997

Fingerprint

Radionuclide Angiography
Epirubicin
Stroke Volume
Lung
Drug Therapy
Doxorubicin
Therapeutics
Cardiotoxicity
Anthracyclines
Secondary Prevention
Guidelines
Injections

Keywords

  • Antimyosin immunoscintigraphy
  • Epirubicin
  • Left ventricular ejection fraction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity. / Maini, Carlo L.; Sciuto, Rosa; Ferraironi, Alessandro; Vici, Patrizia; Tofani, Anna; Festa, Anna; Conti, Francesca; Lopez, Massimo.

In: Journal of Nuclear Cardiology, Vol. 4, No. 6, 11.1997, p. 502-508.

Research output: Contribution to journalArticle

Maini, Carlo L. ; Sciuto, Rosa ; Ferraironi, Alessandro ; Vici, Patrizia ; Tofani, Anna ; Festa, Anna ; Conti, Francesca ; Lopez, Massimo. / Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity. In: Journal of Nuclear Cardiology. 1997 ; Vol. 4, No. 6. pp. 502-508.
@article{bc91061ff6da4d178eefe7779f5a0c43,
title = "Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity",
abstract = "Background. Cardiotoxicity is the major limiting factor in anthracycline chemotherapy of advanced neoplastic disease. Epirubicin shows a more favorable therapeutic index than does doxorubicin, but it is still cardiotoxic. Limited data regarding epirubicin cardiotoxicity are available, and suggested guidelines for doxorubicin with left ventricular ejection fraction (LVEF) measurement may not be empirically useful for epirubicin therapy. This study evaluates the diagnostic role of antimyosin immunoscintigraphy for early identification of patients at risk for late pump dysfunction from cardiotoxicity induced by high-dose administration of epirubicin up to high cumulative dosages. Methods and Results. Chemotherapy with epirubicin was administered to 36 patients with cancer at a dosing rate of 160 mg/m2 as a bolus injection every 21 days to a cumulative dosage of 960 mg/m2. Radionuclide angiography (LVEF) and antimyosin immunoscintigraphy with heart-lung ratio (HLR) measurements were performed before chemotherapy, at intermediate cumulative epirubicin dosages, at the end of treatment, and during the follow-up, LVEF decreased significantly at the end of the treatment and after therapy discontinuation. HLR values were significantly increased at intermediate epirubicin dosage levels and continued to increase to the end of the treatment but thereafter remained substantially unmodified for 3 to 6 months after therapy discontinuation. A value of HLR > 1.85 at intermediate epirubicin dosage level showed a sensitivity of 95{\%} and a specificity of 57{\%} as a predictor of late LVEF impairment. Conclusions. LVEF appears more useful at high cumulative dosages and during follow-up to monitor late pump dysfunction, whereas HLR may be effective during the early phase of the therapy in determining which patients are at risk for development of late cardiac dysfunction.",
keywords = "Antimyosin immunoscintigraphy, Epirubicin, Left ventricular ejection fraction",
author = "Maini, {Carlo L.} and Rosa Sciuto and Alessandro Ferraironi and Patrizia Vici and Anna Tofani and Anna Festa and Francesca Conti and Massimo Lopez",
year = "1997",
month = "11",
doi = "10.1016/S1071-3581(97)90008-8",
language = "English",
volume = "4",
pages = "502--508",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity

AU - Maini, Carlo L.

AU - Sciuto, Rosa

AU - Ferraironi, Alessandro

AU - Vici, Patrizia

AU - Tofani, Anna

AU - Festa, Anna

AU - Conti, Francesca

AU - Lopez, Massimo

PY - 1997/11

Y1 - 1997/11

N2 - Background. Cardiotoxicity is the major limiting factor in anthracycline chemotherapy of advanced neoplastic disease. Epirubicin shows a more favorable therapeutic index than does doxorubicin, but it is still cardiotoxic. Limited data regarding epirubicin cardiotoxicity are available, and suggested guidelines for doxorubicin with left ventricular ejection fraction (LVEF) measurement may not be empirically useful for epirubicin therapy. This study evaluates the diagnostic role of antimyosin immunoscintigraphy for early identification of patients at risk for late pump dysfunction from cardiotoxicity induced by high-dose administration of epirubicin up to high cumulative dosages. Methods and Results. Chemotherapy with epirubicin was administered to 36 patients with cancer at a dosing rate of 160 mg/m2 as a bolus injection every 21 days to a cumulative dosage of 960 mg/m2. Radionuclide angiography (LVEF) and antimyosin immunoscintigraphy with heart-lung ratio (HLR) measurements were performed before chemotherapy, at intermediate cumulative epirubicin dosages, at the end of treatment, and during the follow-up, LVEF decreased significantly at the end of the treatment and after therapy discontinuation. HLR values were significantly increased at intermediate epirubicin dosage levels and continued to increase to the end of the treatment but thereafter remained substantially unmodified for 3 to 6 months after therapy discontinuation. A value of HLR > 1.85 at intermediate epirubicin dosage level showed a sensitivity of 95% and a specificity of 57% as a predictor of late LVEF impairment. Conclusions. LVEF appears more useful at high cumulative dosages and during follow-up to monitor late pump dysfunction, whereas HLR may be effective during the early phase of the therapy in determining which patients are at risk for development of late cardiac dysfunction.

AB - Background. Cardiotoxicity is the major limiting factor in anthracycline chemotherapy of advanced neoplastic disease. Epirubicin shows a more favorable therapeutic index than does doxorubicin, but it is still cardiotoxic. Limited data regarding epirubicin cardiotoxicity are available, and suggested guidelines for doxorubicin with left ventricular ejection fraction (LVEF) measurement may not be empirically useful for epirubicin therapy. This study evaluates the diagnostic role of antimyosin immunoscintigraphy for early identification of patients at risk for late pump dysfunction from cardiotoxicity induced by high-dose administration of epirubicin up to high cumulative dosages. Methods and Results. Chemotherapy with epirubicin was administered to 36 patients with cancer at a dosing rate of 160 mg/m2 as a bolus injection every 21 days to a cumulative dosage of 960 mg/m2. Radionuclide angiography (LVEF) and antimyosin immunoscintigraphy with heart-lung ratio (HLR) measurements were performed before chemotherapy, at intermediate cumulative epirubicin dosages, at the end of treatment, and during the follow-up, LVEF decreased significantly at the end of the treatment and after therapy discontinuation. HLR values were significantly increased at intermediate epirubicin dosage levels and continued to increase to the end of the treatment but thereafter remained substantially unmodified for 3 to 6 months after therapy discontinuation. A value of HLR > 1.85 at intermediate epirubicin dosage level showed a sensitivity of 95% and a specificity of 57% as a predictor of late LVEF impairment. Conclusions. LVEF appears more useful at high cumulative dosages and during follow-up to monitor late pump dysfunction, whereas HLR may be effective during the early phase of the therapy in determining which patients are at risk for development of late cardiac dysfunction.

KW - Antimyosin immunoscintigraphy

KW - Epirubicin

KW - Left ventricular ejection fraction

UR - http://www.scopus.com/inward/record.url?scp=0031453242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031453242&partnerID=8YFLogxK

U2 - 10.1016/S1071-3581(97)90008-8

DO - 10.1016/S1071-3581(97)90008-8

M3 - Article

VL - 4

SP - 502

EP - 508

JO - Journal of Nuclear Cardiology

JF - Journal of Nuclear Cardiology

SN - 1071-3581

IS - 6

ER -